(Total Views: 47)
Posted On: 06/23/2025 4:25:44 PM
Post# of 48
NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Price Target Raised to $15 Following AVERSA Fentanyl Manufacturing Milestone
Nutriband (NASDAQ: NTRB) has received a new $15 price target in an updated report from Robert LeBoyer, Senior Vice President and Equity Research Analyst, Biotechnology, at Noble Capital Markets, following the successful completion of commercial manufacturing and scale-up for AVERSA Fentanyl, its abuse-deterrent transdermal patch developed in partnership with Kindeva.
The report highlights this milestone as a key inflection point that enables Nutriband to initiate production of clinical supplies and proceed with its planned Investigational New Drug (“IND”) application for a Phase 1 trial. The AVERSA program follows the 505(b)(2) regulatory pathway and requires only a single Phase 1 study, aimed at showing reduced appeal to recreational drug users—a step the analyst views as low risk.
LeBoyer raised his FY2027 EPS forecast to $1.57, citing Nutriband’s adherence to timeline projections and avoidance of a previously expected Q1 2025 equity raise. Full-year sales are projected to begin in FY2027, with the NDA submission expected between late 2025 and early 2026.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Nutriband (NASDAQ: NTRB) has received a new $15 price target in an updated report from Robert LeBoyer, Senior Vice President and Equity Research Analyst, Biotechnology, at Noble Capital Markets, following the successful completion of commercial manufacturing and scale-up for AVERSA Fentanyl, its abuse-deterrent transdermal patch developed in partnership with Kindeva.
The report highlights this milestone as a key inflection point that enables Nutriband to initiate production of clinical supplies and proceed with its planned Investigational New Drug (“IND”) application for a Phase 1 trial. The AVERSA program follows the 505(b)(2) regulatory pathway and requires only a single Phase 1 study, aimed at showing reduced appeal to recreational drug users—a step the analyst views as low risk.
LeBoyer raised his FY2027 EPS forecast to $1.57, citing Nutriband’s adherence to timeline projections and avoidance of a previously expected Q1 2025 equity raise. Full-year sales are projected to begin in FY2027, with the NDA submission expected between late 2025 and early 2026.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
